Eledon Pharmaceuticals, Inc. (ELDN)

IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D.

Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have received an average recommendation of "Hold" from the five research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company.

Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified pig kidney into a human at Massachusetts General Hospital Completed $57.5 million financing, with funds expected to support operations into 2Q 2027 IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company.

IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.

Eledon Reports Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation

Eledon Pharmaceuticals, Inc. ( ELDN ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 12, 2025 10:30 AM EST Company Participants Steven Perrin - President, Chief Scientific Officer & Non Independent Director Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Vamil Divan Guggenheim Securities, LLC, Research Division All right. Thanks, everyone, for joining us here on the Second Annual Guggenheim Healthcare Innovation Conference.

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus  Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to advance transplantation programs IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent business highlights.

IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering price of $1.65 per share and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 15,151,515 shares of common stock at a public offering price of $1.649 per pre-funded warrant.

IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Eledon Pharmaceuticals, Inc. ( ELDN ) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros - CEO & Non Independent Director Eliezer Katz - Chief Medical Officer Steven Perrin - President, Chief Scientific Officer & Non Independent Director Paul Little - Chief Financial Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Eledon Pharmaceuticals Phase II BESTOW Results Conference Call.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The company announced results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant.

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m²  Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Conference call to be held Friday, November 7 at 8:00 a.m. ET IRVINE, Calif.

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at Kidney Week